FASN and non-small cell lung carcinoma: Furthermore, Shen et al. demonstrated that FASN inhibition can reduce the expression of PD-1 receptor ligand in non-small-cell lung cancer cells via the “FASN-TGFβ1-PD-L1” axis, and lead to the cytotoxicity of drug-resistant cells to natural killer (NK) cells [8].